nach oben

Erschienen in:

13.05.2017 | Original Article

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

verfasst von: Roger Gilabert-Oriol, Sebastian G. B. Furness, Brett W. Stringer, Alexander Weng, Hendrik Fuchs, Bryan W. Day, Angela Kourakis, Andrew W. Boyd, David L. Hare, Mayank Thakur, Terrance G. Johns, Peter J. Wookey

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

We have reported that calcitonin receptor (CTR) is widely expressed in biopsies from the lethal brain tumour glioblastoma by malignant glioma and brain tumour-initiating cells (glioma stem cells) using anti-human CTR antibodies. A monoclonal antibody against an epitope within the extracellular domain of CTR was raised (mAb2C4) and chemically conjugated to either plant ribosome-inactivating proteins (RIPs) dianthin-30 or gelonin, or the drug monomethyl auristatin E (MMAE), and purified. In the high-grade glioma cell line (HGG, representing glioma stem cells) SB2b, in the presence of the triterpene glycoside SO1861, the EC₅₀ for mAb2C4:dianthin was 10.0 pM and for mAb2C4:MMAE [antibody drug conjugate (ADC)] 2.5 nM, 250-fold less potent. With the cell line U87MG, in the presence of SO1861, the EC₅₀ for mAb2C4:dianthin was 20 pM, mAb2C4:gelonin, 20 pM, compared to the ADC (6.3 nM), which is >300 less potent. Several other HGG cell lines that express CTR were tested and the efficacies of mAb2C4:RIP (dianthin or gelonin) were similar. Co-administration of the enhancer SO1861 purified from plants enhances lysosomal escape. Enhancement with SO1861 increased potency of the immunotoxin (>3 log values) compared to the ADC (1 log). The uptake of antibody was demonstrated with the fluorescent conjugate mAb2C4:Alexa Fluor 568, and the release of dianthin-30:Alexa Fluor488 into the cytosol following addition of SO1861 supports our model. These data demonstrate that the immunotoxins are highly potent and that CTR is an effective target expressed by a large proportion of HGG cell lines representative of glioma stem cells and isolated from individual patients.

Nur mit Berechtigung zugänglich

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021CrossRefPubMed

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111CrossRefPubMed

Fomchenko EI, Holland EC (2005) Stem cells and brain cancer. Exp Cell Res 306:323–329CrossRefPubMed

Das S, Marsden PA (2013) Angiogenesis in glioblastoma. N Engl J Med 369:1561–1563CrossRefPubMedPubMedCentral

Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331CrossRefPubMed

Hamilton GS (2015) Antibody–drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids. Biologicals 43:318–332. doi:10.1016/j.biologicals.2015.05.006 CrossRefPubMed

de Goeij BE, Lambert JM (2016) New developments for antibody–drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14–23CrossRefPubMed

Ledford H (2016) Weaponized antibodies use new tricks to fight cancer. Nature 540:19–20CrossRefPubMed

10.

Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK (2016) Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. doi:10.1093/neuonc/now257

11.

Fermani S, Falini G, Ripamonti A, Bolognesi A, Polito L, Stirpe F (2003) Crystallization and preliminary X-ray diffraction analysis of two ribosome-inactivating proteins: lychnin and dianthin 30. Acta Crystallogr D Biol Crystallogr 59:1227–1229CrossRefPubMed

12.

Hosur MV, Nair B, Satyamurthy P, Misquith S, Surolia A, Kannan KK (1995) X-ray structure of gelonin at 1.8 A resolution. J Mol Biol 250:368–380CrossRefPubMed

13.

von Mallinckrodt B, Thakur M, Weng A, Gilabert-Oriol R, Durkop H, Brenner W, Lukas M, Beindorff N, Melzig MF, Fuchs H (2014) Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma. Future Oncol 10:2161–2175CrossRef

14.

Thakur M, Mergel K, Weng A, von Mallinckrodt B, Gilabert-Oriol R, Durkop H, Melzig MF, Fuchs H (2013) Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: an evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice. Mol Oncol 7:475–483CrossRefPubMed

15.

Weng A, Manunta MD, Thakur M, Gilabert-Oriol R, Tagalakis AD, Eddaoudi A, Munye MM, Vink CA, Wiesner B, Eichhorst J, Melzig MF, Hart SL (2015) Improved intracellular delivery of peptide- and lipid-nanoplexes by natural glycosides. J Control Release 206:75–90. doi:10.1016/j.jconrel.2015.03.007 CrossRefPubMed

16.

Furness SG, Liang YL, Nowell CJ, Halls ML, Wookey PJ, Dal Maso E, Inoue A, Christopoulos A, Wootten D, Sexton PM (2016) Ligand-dependent modulation of g protein conformation alters drug efficacy. Cell 167(739–749):e11. doi:10.1016/j.cell.2016.09.021

17.

Wookey P, Zulli A, Lo C, Hare D, Schwarer A, Darby I, Leung A (2010) Calcitonin receptor (CTR) expression in embryonic, foetal and adult tissues: developmental and pathophysiological implications. In: Hay D, Dickerson I (eds) The calcitonin gene-related peptide family; form, function and future perspectives. Springer, The Netherlands, pp 199–233CrossRef

18.

Wookey PJ, Turner K, Furness JB (2012) Transient expression of the calcitonin receptor by enteric neurons of the embryonic and early post-natal mouse. Cell Tissue Res 347:311–317CrossRefPubMed

19.

Marx SJ, Aurbach GD, Gavin JR 3rd, Buell DW (1974) Calcitonin receptors on cultured human lymphocytes. J Biol Chem 249:6812–6816PubMed

20.

Body JJ, Glibert F, Nejai S, Fernandez G, Van Langendonck A, Borkowski A (1990) Calcitonin receptors on circulating normal human lymphocytes. J Clin Endocrinol Metab 71:675–681CrossRefPubMed

21.

Jagger C, Chambers T, Pondel M (2000) Transgenic mice reveal novel sites of calcitonin receptor gene expression during development. Biochem Biophys Res Commun 274:124–129CrossRefPubMed

22.

Tikellis C, Xuereb L, Casley D, Brasier G, Cooper ME, Wookey PJ (2003) Calcitonin receptor isoforms expressed in the developing rat kidney. Kidney Int 63:416–426CrossRefPubMed

23.

Tolcos M, Tikellis C, Rees S, Cooper M, Wookey P (2003) Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. J Comp Neurol 456:29–38CrossRefPubMed

24.

Furness SGB, Hare DL, Kourakis A, Turnley AM, Wookey PJ (2016) A novel ligand of calcitonin receptor reveals a potential new sensor that modulates programmed cell death. Cell Death Discov 2:16062. doi:10.1038/cddiscovery.2016.62 (eCollection 2016) CrossRefPubMedPubMedCentral

25.

Wookey PJ, McLean CA, Hwang P, Furness SG, Nguyen S, Kourakis A, Hare DL, Rosenfeld JV (2012) The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172. Histopathology 60:895–910. doi:10.1111/j.1365-2559.2011.04146.x CrossRefPubMed

26.

Silvestris F, Cafforio P, De Matteo M, Quatraro C, Dammacco F (2008) Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 32:611–623CrossRefPubMed

27.

Venkatanarayan A, Raulji P, Norton W, Chakravarti D, Coarfa C, Su X, Sandur SK, Ramirez MS, Lee J, Kingsley CV, Sananikone EF, Rajapakshe K, Naff K, Parker-Thornburg J, Bankson JA, Tsai KY, Gunaratne PH, Flores ER (2015) IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 517:626–630CrossRefPubMed

28.

Nicholson GC, Horton MA, Sexton PM, D’Santos CS, Moseley JM, Kemp BE, Pringle JA, Martin TJ (1987) Calcitonin receptors of human osteoclastoma. Horm Metab Res 19:585–589CrossRefPubMed

29.

Gorn AH, Rudolph SM, Flannery MR, Morton CC, Weremowicz S, Wang TZ, Krane SM, Goldring SR (1995) Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction. J Clin Invest 95:2680–2691CrossRefPubMedPubMedCentral

30.

Gillespie M, Thomas R, Pu Z, Zhou H, Martin T, Findlay D (1997) Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 73:812–815CrossRefPubMed

31.

Wu G, Burzon D, di Sant’Agnese P, Schoen S, Deftos L, Gershagen S, Cockett A (1996) Calcitonin receptor mRNA expression in human prostate. Urology 47:376–381CrossRefPubMed

32.

Thomas S, Muralidharan A, Shah GV (2007) Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol 31:1425–1437PubMed

33.

Frendo JL, Delage-Mourroux R, Cohen R, Pichaud F, Pidoux E, Guliana JM, Jullienne A (1998) Calcitonin receptor mRNA is expressed in human medullary thyroid carcinoma. Thyroid 8:141–147CrossRefPubMed

34.

Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287CrossRefPubMed

35.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral

36.

Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhauser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW (2013) EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238–248CrossRefPubMed

37.

Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4:568–580CrossRefPubMed

38.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465CrossRefPubMed

39.

Grundy TJ, De Leon E, Griffin KR, Stringer BW, Day BW, Fabry B, Cooper-White J, O’Neill GM (2016) Differential response of patient-derived primary glioblastoma cells to environmental stiffness. Sci Rep 6:23353CrossRefPubMedPubMedCentral

40.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL (2014) The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol 35:1459–1465CrossRefPubMed

41.

Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay M, Martin JH (2015) The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neuro Oncol 122:263–271CrossRef

42.

Dickinson A, Yeung KY, Donoghue J, Baker MJ, Kelly RD, McKenzie M, Johns TG, St John JC (2013) The regulation of mitochondrial DNA copy number in glioblastoma cells. Cell Death Differ 20:1644–1653CrossRefPubMedPubMedCentral

43.

Gilabert-Oriol R, Weng A, Trautner A, Weise C, Schmid D, Bhargava C, Niesler N, Wookey PJ, Fuchs H, Thakur M (2015) Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861. Biochem Pharmacol 97:247–255CrossRefPubMed

44.

Rosenblum MG, Kohr WA, Beattie KL, Beattie WG, Marks W, Toman PD, Cheung L (1995) Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J Interf Cytokine Res 15:547–555CrossRef

45.

Cumber AJ, Henry RV, Parnell GD, Wawrzynczak EJ (1990) Purification of immunotoxins containing the ribosome-inactivating proteins gelonin and momordin using high performance liquid immunoaffinity chromatography compared with blue sepharose CL-6B affinity chromatography. J Immunol Methods 135:15–24CrossRefPubMed

46.

Weng A, Thakur M, von Mallinckrodt B, Beceren-Braun F, Gilabert-Oriol R, Wiesner B, Eichhorst J, Böttger S, Melzig MF, Fuch H (2012) Saponins modulate the intracellular trafficking of protein toxins. J Control Release 164:74–86. doi:10.1016/j.jconrel.2012.10.002 CrossRefPubMed

47.

Seck T, Baron R, Horne WC (2003) Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem 278:10408–10416CrossRefPubMed

48.

Ross JL, Ali MY, Warshaw DM (2008) Cargo transport: molecular motors navigate a complex cytoskeleton. Curr Op Cell Biol 20:41–47CrossRefPubMedPubMedCentral

49.

Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC (2009) Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 32:574–584CrossRefPubMed

Titel: Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma
verfasst von: Roger Gilabert-Oriol
Sebastian G. B. Furness
Brett W. Stringer
Alexander Weng
Hendrik Fuchs
Bryan W. Day
Angela Kourakis
Andrew W. Boyd
David L. Hare
Mayank Thakur
Terrance G. Johns
Peter J. Wookey
Publikationsdatum: 13.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 9/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2013-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity

MuPeXI: prediction of neo-epitopes from tumor sequencing data

Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies

FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia

Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie